Where We Were and Where We Are in NMIBC Trials and Therapies

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In the third part of this roundtable, Gordon Brown, DO, Tim Richardson, MD, Bryan Mehlhaff, MD, Chris Pieczonka, MD, and Gene Cone, MD, explore advancements in treating high-risk, non-muscle invasive bladder cancer (NMIBC), focusing on the BCG-refractory population. They discuss the evolution from early therapies like valrubicin to more recent options, including pembrolizumab, nadofaragene firadenovec, oportuzumab monatox, and the TAR-200 device, which offers extended intravesical gemcitabine delivery. The panel examines improved complete response rates, manageable toxicity profiles, and strategies for mitigating lower urinary tract symptoms. Emphasizing patient education and practical management approaches, the discussion highlights how these innovations enhance treatment outcomes while maintaining quality of care.

#bladdercancer #cancer #oncology #urooncology #urology #healthcare
Category
Urology
Be the first to comment

Up Next